Published • loading... • Updated
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
- AstraZeneca has exercised its option to obtain an exclusive global license for PTX-299, a bispecific antibody degrader targeting EGFR, from Pinetree Therapeutics.
- This option exercise follows encouraging preclinical progress and marks a key milestone in collaboration between Pinetree Therapeutics and AstraZeneca.
- AstraZeneca will take responsibility for global development and commercialization of PTX-299 under the agreement.
- Pinetree Therapeutics will receive a $25 million payment due to AstraZeneca's option exercise, with the total potential value of the agreement exceeding $500 million.
Insights by Ground AI
31 Articles
31 Articles
Coverage Details
Total News Sources31
Leaning Left3Leaning Right6Center11Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
15%
C 55%
R 30%
Factuality
To view factuality data please Upgrade to Premium
